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Abstract 35 
Shifts in microbial communities are implicated in the pathogenesis of a number of 36 
gastrointestinal diseases, but we have limited understanding of the mechanisms 37 
that lead to altered community structures. One difficulty with studying these 38 
mechanisms in human subjects is the inherent baseline variability of the 39 
microbiota in different individuals that arise due to varying life histories. To try 40 
and overcome this baseline variability we employed a mouse model to control 41 
host genotype, diet and other possible influences on the microbiota. This allowed 42 
us to determine if the indigenous microbiota in such mice had a stable baseline 43 
community structure and whether this community exhibited a consistent 44 
response following antibiotic administration. We employed a tag sequencing 45 
strategy targeting the V6 hypervariable region of the bacterial small-subunit (16S) 46 
ribosomal RNA combined with massively parallel sequencing to determine the 47 
community structure of the gut microbiota. Inbred mice in a controlled 48 
environment harbored a reproducible baseline community that was significantly 49 
impacted by antibiotic administration. The ability of the gut microbial community 50 
to recover to baseline following cessation of antibiotic administration varied 51 
according to the antibiotic regimen administered. Severe antibiotic pressure 52 
resulted in reproducible long-lasting alterations in the gut microbial community 53 
including a decrease in overall diversity. The finding of stereotypic responses of 54 
the indigenous microbiota to ecologic stress implies that a better understanding 55 
of the factors that govern community structure could lead to strategies for the 56 
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intentional manipulation of this ecosystem to preserve or restore a healthy 57 
microbiota. 58 
 5 
Introduction 59 
A highly diverse, complex community of microorganisms inhabits the 60 
gastrointestinal tract of mammals. This community, referred to as the indigenous 61 
microbiota, exists in a delicate symbiosis with the host (3, 15). A significant body 62 
of research has demonstrated that disturbances in this balance can disrupt 63 
intestinal homeostasis. Multiple disease states may arise, at least in part, in 64 
response to altered indigenous microbial communities in the gut (10, 47, 53, 56). 65 
Conversely, research on probiotics indicates the normal balance between the 66 
indigenous microbiota and the host can be protected or restored through 67 
administration of beneficial microbes (6, 45, 60). 68 
The relationship between the indigenous microbiota and a host involves 69 
multiple interactions. The indigenous microbiota play a central role in digestion 70 
and nutrition of the host (30, 56). These microbes also affect the regulation and 71 
homeostasis of the host immune system (27, 46). As part of the innate defenses 72 
of the gastrointestinal tract, the community of indigenous microbes forms and 73 
ecologic barrier that prevents the ingress of pathogenic microorganisms. For 74 
example, the development of Clostridium difficile-associated colitis following 75 
antibiotic administration arises from a loss of intrinsic “colonization resistance” 76 
against pathogenic organisms (61). Antibiotic disturbance of the normal 77 
community structure of the microbiota may allow germination of environmentally 78 
acquired spores with subsequent overgrowth of the pathogen and toxin 79 
production. Alternatively, C. difficile colitis may develop subsequent to the 80 
expansion of low-abundance C. difficile populations that normally produce 81 
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insignificant levels of toxin. In either case, the disruption of the indigenous 82 
microbiota by antibiotic administration is a key component of pathogenesis (7). 83 
Murine models have provided important insights about the interactions 84 
between the microbiota and the host. One consistent feature of microbiota 85 
studies in human subjects is that there is significant interindividual variation in the 86 
indigenous microbiota (12, 13). This variation likely arises from the accumulated 87 
effects of genetic and environmental influences on the gut microbial community 88 
(11). Significant baseline variation makes it difficult to conduct studies that follow 89 
the dynamics of the gut microbiota in humans, especially if the goal is to discern 90 
stereotypic responses to a given manipulation. Therefore, as with other areas of 91 
biomedical research, murine models offer unique advantages for microbiota 92 
experimentation. 93 
Several recent studies describe murine models of disease in which altered 94 
indigenous gut microbial communities are generated through the administration 95 
of antibiotics. These altered communities can either be permissive or required for 96 
the development of the model disease state, although in other cases they appear 97 
to be protective (5, 9, 24, 26, 52). Although these studies have provided insight 98 
into many of the host responses to the indigenous microbiota, we have 99 
remarkably little information as to the exact nature of the effect of antibiotic 100 
administration on the microbial communities themselves. For example, these 101 
studies assume that genetically identical mice would harbor a consistent baseline 102 
microbiota. Furthermore, it is also assumed that the microbiota respond in a 103 
reproducible manner to the antibiotic administration resulting in consistent 104 
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changes in the structure and function of the microbiota responsible for the 105 
observed changes in the host response. These crucial assumptions have not 106 
been rigorously tested to date. 107 
Early studies on the gut microbiota relied upon culture-based techniques 108 
that characterizes only a small fraction of the microbial diversity present (19). The 109 
introduction of molecular techniques e.g. DNA sequencing of PCR amplicons 110 
from ribosomal RNA genes, allowed the detection and enumeration of 111 
microorganisms that are refractory to cultivation (41, 62). Each sequence serves 112 
as a proxy for the occurrence of a microbial genome in a microbial community. 113 
Most of the amplicon sequences from the human gut microbiota correspond to 114 
Firmicutes or Bacteroidetes (13) and their total complexity exceeds 15,000 115 
different operational taxonomic units (OTUs) (42).  116 
 For most complex microbial communities including the gut microbiota, a 117 
small number of phylotypes dominate population structures and mask the 118 
appearance of many distinct but low-abundance taxa in most molecular surveys 119 
(55). A meaningful comparison of microbial population structures for different 120 
complex communities requires analysis of many thousands of PCR amplicon 121 
sequences in order to estimate the relative abundance of different phylotypes 122 
and to detect the presence of rare taxa. Recent advances in DNA sequencing 123 
technology have permitted the development of methods for deep culture-124 
independent surveys of microbial diversity at relatively low cost. In this 125 
communication we conducted controlled experiments to characterize the 126 
changes in the community structure of the murine gastrointestinal microbiota 127 
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during antibiotic administration and to monitor the response of this community 128 
after withdrawal of drug. Using a high-throughput 16S tag sequencing approach 129 
targeting the V6 hypervariable region (21, 55), we gained an unprecedented view 130 
of the diversity present in the gut microbiota and were able to detail the dynamics 131 
of the gut microbial community during periods of ecologic stress brought on by 132 
antibiotic administration. We find that antibiotic administration results in 133 
reproducible, significant, and in some cases, long lasting, changes in the 134 
community structure of the gut microbiota. These changes most likely disturb the 135 
balanced interactions between the indigenous microbiota and the host and 136 
account for observed changes in gut homeostasis that have been shown to result 137 
from antibiotic administration in both clinical and experimental settings. 138 
Materials and Methods 139 
Mouse models and housing conditions. C57BL/6 IL-10-/- mice were from a 140 
breeding colony maintained in specific pathogen free conditions at Michigan 141 
State University (MSU), derived from mice originally purchased from Jackson 142 
Laboratories (Bar Harbor, ME). C57BL/6J wild-type mice were purchased directly 143 
from Jackson Laboratories and housed with autoclaved food, bedding, and 144 
water. For the antibiotic therapy experiments selected four- to six-week old mice 145 
were either treated with antibiotics supplemented in their food (amoxicillin [3.0 146 
mg], metronidazole [0.69 mg] and bismuth [0.185 mg] formulated per 5 gram 147 
tablet/day/average [20 g] mouse [BioServ, Frenchtown, NJ]) or in their drinking 148 
water (cefoperazone [0.5 mg/mL] [Sigma-Aldrich]). Experiments with amoxicillin, 149 
metronidazole and bismuth were carried out at the University Research 150 
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Containment Facility at MSU and the experiments with cefoperazone were 151 
carried out in the Unit for Laboratory Animal Medicine at the University of 152 
Michigan. All experimental protocols were approved the animal use and care 153 
committees at the respective institutions. 154 
Sample collection and DNA extraction. At the conclusion of the experiments, 155 
mice were euthanized by CO2 asphyxiation. The cecum of each mouse was 156 
removed and washed in phosphate-buffered saline to remove luminal contents. 157 
The cecal tip was then excised, bisected, and snap-frozen in liquid nitrogen prior 158 
to storage at -80º C. Genomic DNA was then extracted from cecal tip samples 159 
(25-100 mg) with the QIAGEN DNeasy® Blood & Tissue Kit using a modified 160 
protocol.  These modifications included: (1) adding a bead beating step using 161 
UltraClean™ Fecal DNA Bead Tubes (MO BIO Laboratories, Inc.) that were 162 
shaken using a MiniBeadbeater-8™ (BioSpec Products, Inc.) at the 163 
“homogenize” setting for one minute; (2) increasing the amount of Buffer ATL 164 
used in the initial steps of the protocol (from 180 µL to 360 µL); (3) increasing the 165 
volume of proteinase K used (from 20 µL to 40 µL); and (4) decreasing the 166 
amount of Buffer AE used to elute the DNA at the end of the protocol (decreased 167 
from 200 µL to 100 µL). 168 
Sequencing and data analysis.  The data presented here are based on 39 PCR 169 
amplicon libraries sequenced in five 454 runs using the GS-FLX platform (454 170 
Life Sciences, Roche Diagnostics Corp).  V6 tag sequence amplicon libraries 171 
were constructed as previously described (54).  Primer sets corresponding to 172 
967F and 1046R used in the library preparation and the permuted primer 173 
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approach for sequencing multiple libraries within a single GS-FLX 454 run 174 
without use of a physical partition are described in Huber et al., 2007 (21). 175 
Primers were trimmed off and all sequences without an exact match to the 176 
forward primer, shorter than 50 nt, or containing ambiguous base calls were 177 
removed as low quality reads. Sequences were organized in a relational 178 
database, and operational taxonomic units were created by aligning with 179 
MUSCLE and clustering with DOTUR as described in Huber et al., 2007 (14, 21, 180 
50).  Taxonomic assignments were made through direct comparison of tags to a 181 
reference database of close to 200,000 distinct V6 sequences and using a 182 
consensus of the nearest tags in a global alignment of tags and reference 183 
sequences (22).  184 
Quantitative PCR.  Quantitative PCR reactions were used to separately assay 185 
the quantity of rRNA operons in the DNA samples relative to a singe-copy host 186 
gene (mouse TNF-α).  A portion of the 16S rRNA encoding gene from 187 
Helicobacter hepaticus 3B1 was cloned and used as a positive control (between 188 
positions 331 and 797 based on Escherichia coli numbering of the 16S rRNA 189 
gene).  A 264-bp portion of the gene encoding TNF- α from Mus musculus was 190 
also cloned and used as a positive control for the host gene target (between 191 
positions 6455 and 6718 of the mouse TNF- α encoding gene; GenBank 192 
accession number Y00467).  Plasmids were purified from each clone and a 10-193 
fold dilution series was used to determine detection limits of the assay as well as 194 
provide standard curves for absolute quantification in the qPCR reactions (range 195 
of 101-107 copies per reaction).  Assay volumes were comprised of the 196 
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LightCycler® 480 Probes Master reaction mix (Roche) at 1x concentration, and 197 
appropriate primer-probe sets to increase specificity of the detected signals from 198 
the sample DNA (100 ng).  For detection of the bacterial signal 100 nanomoles of 199 
each of the forward and reverse primers and the fluorogenic probe were included 200 
in the reactions.  Sequences for the forward primer (5’-201 
TCCTACGGGAGGCAGCAGT-3’), the reverse primer (5’-202 
GGACTACCAGGGTATCTAATCCTGTT-3’), and the probe (5’-[6-FAM]-203 
CGTATTACCGCGGCTGCTGGCAC-[TAMRA]-3’) were based on Nadkarni et al., 204 
2002 (39).  Final assay volumes of 20 µL were dispensed in triplicate in 96-well 205 
plates.  Signals were detected with a LightCycler 480   instrument (Roche).  The 206 
reaction conditions for amplification of DNA were 95 °C for 10 minutes and 40 207 
cycles of 95 °C for 15 seconds and 60 °C for 1 minute.  Detection of the host 208 
signal used 200 nanomoles of the forward (TNFa_mu_se; 5’-209 
GGCTTTCCGAATTCACTGGAG-3’) and reverse primers (TNFa_mu_as; 5’-210 
CCCCGGCCTTCCAAATAAA-3’), and 100 nanomoles of the probe 211 
(TNFa_mu_probe; 5’-[Cy5]-ATGTCCATTCCTGAGTTCTGCAAAGGGA-[Iowa 212 
Black RQ™]-3’) adapted from Nitsch et al., 2001 (40).  Amplification of the host 213 
signal began with an incubation at 95°C for 10 minutes, followed by 45 cycles of 214 
95°C for 20 seconds and 64°C for 30 seconds. Comparison in relative bacterial 215 
load was performed via the ∆∆CT method normalizing the 16S signal to the host 216 
signal (51). 217 
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Results 218 
Antibiotic administration alters the structure of the gut microbiota 219 
To characterize the impact of antibiotic administration on the composition 220 
of the gut microbiota, a combination of amoxicillin, metronidazole and bismuth 221 
(AMB) was administered to C57BL/6 IL-10-/- mice via their chow for 10 days 222 
(Figure 1). The C57BL/6 IL-10-/- strain was chosen as it is utilized as model of 223 
inflammatory bowel disease that is responsive to antibiotic therapy (33). The 224 
microbial community in one group of mice was assessed immediately following 225 
the 10-day treatment, while a second group of mice was switched back to drug 226 
free chow for two weeks before microbial community analysis.  The microbiota 227 
from mice in both groups were compared to a group of control mice that had 228 
been fed conventional chow for the duration of the study. 229 
 We used a massively-parallel pyrosequencing strategy to retrieve 230 
sequences of the V6 hypervariable region of the small-subunit (SSU) rRNA gene 231 
(55) to determine the composition of the microbial community associated with the 232 
cecal mucosal of these was mice. These SSU sequence tags are generated by 233 
PCR amplification and function as proxies for the presence of individual 234 
phylotypes present in a given community. The use of pyrosequencing permitted 235 
characterization of a greater number of phylotypes than previously practical via 236 
PCR amplification, cloning and capillary sequencing of SSU genes. GAST 237 
(Global Alignment for Sequence Taxonomy) provided taxonomic assignments for 238 
each of the tag sequences (22). 239 
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 We collected a total of 1,006,137 sequence tags were generated from 240 
representative samples (9 control, 2 treated and 10 treated followed by 241 
recovery). The vast majority of the sequence tags recovered from the cecal 242 
community of control animals affiliated with the phyla Bacteroidetes and 243 
Firmicutes, with only about 1% belonging to Proteobacteria (Figure 2, Table S1). 244 
In the antibiotic-treated animals however, the majority of tags (73,010 of 102,822, 245 
[71%]) were Proteobacteria. Two specific tags, assigned to the family 246 
Enterobacteriaceae accounted for 67,717 (93%) of these Proteobacteria tags 247 
(Table S2). In the control animals, these two tags represented only 106 out of a 248 
total of 5214 (2%) tags belonging to Proteobacteria. 249 
 In the animals whose gut microbial community was allowed to recover via 250 
a two-week antibiotic-free period, Firmicutes and Bacteroidetes returned to 251 
dominance (70% and 22% of the total number of tags, respectively). 252 
Proteobacteria decreased to 5.77% of the total, greater than the 1.2% in the 253 
animals that never received antibiotics, but much less than the 73% that they 254 
comprised at the end of the AMB treatment (Figure 2). The relative increase in 255 
Proteobacteria resulted from increases in tags that mapped to several taxonomic 256 
groups within the phylum (Table S1). The two Enterobacteriaceae tags that were 257 
dominant in the AMB-treated mice were encountered only 201 times out of a total 258 
of 26,964 (0.75%) Proteobacteria tags (Table S2). 259 
 A global comparison of all of the gut microbial communities in each of the 260 
animals was performed by calculating the Bray-Curtis measure of community 261 
similarity (34). This index is based upon presence/absence and relative 262 
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abundance of each phylotype encountered the mucosa-associated communities. 263 
We calculated the average Bray-Curtis similarity for each pair-wise comparison 264 
of the control, treated and recovered animals (Table 1). ANOVA of these Bray-265 
Curtis values confirmed that the mucosa-associated microbiota from antibiotic 266 
treated animals differed significantly from both the control animals and the 267 
recovered animals (p < 0.05). The average Bray-Curtis similarity comparing 268 
communities from antibiotic-treated animals to communities from the other two 269 
experimental groups was significantly lower.  270 
Variability in the murine gut microbiota  271 
 Despite the significant differences in the gut microbiota between control 272 
animals and animals that received the triple antibiotic cocktail, there was still 273 
inter-animal variation noted within each experimental group. The animals in this 274 
experiment were selected from a breeding colony maintained at Michigan State 275 
University over a time period of approximately 5 months. The animals therefore 276 
came from several different litters born to separate mothers. 277 
To determine the degree of similarity amongst animals that shared as 278 
many variables as possible, we sequenced and compared 48,594 V6 sequence 279 
tags from the mucosa-associated microbiota located in the cecae of three age-280 
matched, wild-type C57BL/6 mice purchased from a commercial vendor. Figure 3 281 
depicts the results of taxonomic assignments and Bray-Curtis measures of 282 
community similarity based upon presence/absence and relative phylotype 283 
abundance from the mucosa-associated community of each animal. As observed 284 
previously, Firmicutes and Bacteroidetes dominated the microbial communities in 285 
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the cecae of each of the three animals. All three communities displayed similar 286 
phylotype distributions at all taxonomic levels with Bray-Curtis similarities > 0.9 287 
for all pairwise community comparisons.  We recovered approximately 16,000 288 
tags from each community (Figure 3). Using an operational taxonomic unit (OTU) 289 
assignment of 97% sequence similarity, this yielded ~1000 OTUs in each 290 
community. The non-parametric Chao1 estimator (8), suggests that for this 291 
sampling effort, there are ~1200 unique 97% OTUs in each mucosa-associated 292 
gut community. 293 
Antibiotic administration can result in a prolonged decrease in the 294 
diversity of the gut microbiota 295 
 In spite of the dramatic shifts in the composition of the gut microbiota 296 
following administration of the amoxicillin, metronidazole and bismuth cocktail, 297 
the community structure returned largely to the baseline state two weeks after 298 
discontinuation of the drugs. In an additional pilot experiment, the broad-299 
spectrum cephalosporin antibiotic cefoperazone appeared to have a similar 300 
dramatic effect on the microbiota of C57BL/6 IL-10-/- mice, but in this case there 301 
were significant long-term effects on the community structure, including lower 302 
overall diversity, after antibiotic recovery (data not shown). 303 
To extend this initial observation, we undertook an additional antibiotic 304 
administration trial employing cefoperazone in twenty female wild type C57BL/6 305 
mice (Figure 1B). Five mice were maintained in a single cage on standard mouse 306 
chow and sterile water (control group). The remaining 15 mice were switched to 307 
water supplemented with cefoperazone (0.5 mg/mL) and after 10 days, these 308 
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antibiotic-treated mice were divided into three subsequent treatments. Three 309 
mice were immediately euthanized to observe the effects of cefoperazone on the 310 
gut microbiota. Six mice, housed three animals per cage, were returned to sterile 311 
water for six weeks (isolated recovery) while another group of six mice (again 312 
divided into two cages) were housed with a control mouse added to each cage 313 
during the antibiotic-free period (donor recovery). The addition of the control 314 
mouse allowed reinoculation of the gut microbiota via natural coprophagic 315 
activity.  316 
We recovered a total of 308,505 tag sequences were recovered from the 317 
seventeen samples representing the animals in the three experimental groups 318 
(Table S3). On average ~18,000 high quality sequence tags (23) were recovered 319 
per sample. Amplification of sequence tags was not possible for the three 320 
cefoperazone-treated mice that were euthanized at the end of antibiotic 321 
treatment (without a drug-free recovery period). Real-time PCR targeting the 16S 322 
SSU gene was used to determine to what effect the antibiotics had on overall 323 
bacterial load (judged by the relative ratio of the 16S SSU signal to a genomic 324 
murine target gene), and whether this could explain the inability to amplify 325 
sequence tags from these animals. The bacterial load in animals treated with 326 
antibiotics decreased by three orders of magnitude (average fold change 4300) 327 
compared to control animals. Both groups of animals that were allowed to 328 
recover from antibiotic administration for 6 weeks (isolated recovery and donor 329 
recovery) had levels of bacteria that were comparable to the control animals 330 
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(average fold change 0.91 for donor recovery animals and 1.20 for isolated 331 
recovery animals). 332 
 Pairwise Bray-Curtis similarities are displayed in heatmap format (Figure 333 
4) to allow visualization of all of the pair-wise comparisons. The bacterial 334 
community in cefoperazone-treated animals six weeks after discontinuation of 335 
the drug was distinct from that in control animals. However, the microbial 336 
community in the animals that recovered from antibiotic-administration in the 337 
presence of an untreated donor animal returned to a state that was very similar 338 
to that seen in the control animals.  339 
 When we examined the composition of the phylotypes at the level of 340 
phylum, the primary distinction was a reduction of Bacteroidetes diversity in the 341 
animals that recovered without additional input of microbes. While phylotypes 342 
assigned to Bacteroidetes comprised about 15% of the total community in the 343 
control animals and in the animals that recovered in the presence of a donor 344 
animals, they were only 0.33% of the total community in the animals that 345 
recovered in the absence of a donor.  346 
 At finer levels of taxonomic distinction, there were additional differences 347 
noted between the animals that did not have a donor animal present during the 348 
recovery phase compared to either the control animals or those that recovered 349 
with a donor (Figure 5 Table S3). At the genus level, the composition of the 350 
microbial community from controls and recovery with donor animals was quite 351 
different from the composition of the community from animals that recovered 352 
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without a donor. These data also suggest that the gut community in animals that 353 
recovered without a donor was composed of a decreased number of phylotypes. 354 
 Rarefaction curves demonstrated there were fewer phylotypes present in 355 
the microbial community from animals that recovered without a donor. 356 
Rarefaction analysis involves resampling of community survey data to generate 357 
idealized collector’s curves, providing an indication of overall phylotype richness 358 
(17, 34). In addition, rarefaction can provide an estimate of the depth to which a 359 
complex community has been sampled. Rarefaction curves from the control 360 
animals and the animals that recovered in the presence of a donor overlapped, 361 
confirming that the overall diversity (phylotype richness) was similar between the 362 
two (Figure 6). Conversely, rarefaction analysis of the communities from the 363 
animals that recovered without a donor indicated that the diversity of these 364 
communities was lower than for the other two experimental groups. 365 
Discussion 366 
The myriad interactions between the indigenous gastrointestinal 367 
microbiota and their mammalian host have been a focus of considerable recent 368 
scientific investigation.  Studies on human subjects have the advantage of 369 
directly examining the natural community responsible for specific diseases. 370 
However, due to technical and ethical constraints of examining the human 371 
microbiota, a great deal of effort has been applied to studying model systems, in 372 
particular murine models.  373 
Two main lines of research have provided insights about host/microbiota 374 
interactions in murine models. Studies in germ free and gnotobiotic mice have 375 
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demonstrated that gut bacteria can transmit signals that influence host responses 376 
(20, 44). However, these are highly simplified systems where community 377 
complexity is orders of magnitude lower than naturally occurring murine 378 
microbiota. An alternative approach has been to study ecologic stressors shape 379 
complex communities in murine model systems. In many cases antibiotics are 380 
employed to alter the indigenous microbiota thus disturbing the normal, baseline 381 
host/microbe interactions. Such an approach has demonstrated a role for the 382 
microbiota in genetic models of murine inflammatory bowel disease (26, 33) and 383 
in the modulation of glucose tolerance in mouse models of insulin resistance 384 
(37). Antibiotic treatment studies have shown that antibiotic resistant bacterial 385 
pathogens can exploit innate immune deficits triggered by antibiotic 386 
administration (5).  Antibiotic regimens have been used to demonstrate a role for 387 
the indigenous microbiota in shaping physiologic responses of the gut mucosa 388 
including mediating protective responses to direct epithelial injury (43) and 389 
directing the differentiation of IL-17-producing T-helper cells in the mucosa of the 390 
small intestine (24).  Antibiotic treated mice demonstrate altered susceptibility to 391 
experimental infection with pathogenic bacteria. Streptomycin treatment of mice 392 
increases susceptibility to oral infection with Salmonella enterica serovar 393 
Typhimurium (52). A recently described murine model of Clostridium difficile-394 
associated colitis employed pretreatment with a mixture of five antibiotics 395 
followed by a single dose of clindamycin a day prior to oral challenge with C. 396 
difficile (9).  397 
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The focus of these studies has generally been on the host response to the 398 
alteration in the indigenous microbiota. In most cases the nature of the antibiotic-399 
induced changes on the microbiota were not investigated. Some studies 400 
measured changes in total aerobic and anaerobic colts available bacteria 401 
following antibiotic administration and in a few cases limited culture-independent 402 
investigation of the microbiota was performed. An implicit assumption for these 403 
studies is that genetically identical mice harbor a consistent baseline microbiota. 404 
A further assumption is that the use of antibiotics would result in reproducible 405 
changes in the microbiota that were responsible for the altered host responses 406 
observed. This critical assumption has never been formally addressed in detail 407 
until the current study.  408 
It has been proposed that an adult mammal harbors a stable, “climax 409 
community” in each anatomic area of the GI tract (48). Although there can be 410 
individual variation in the composition of shallow phylogenetic lineages within the 411 
gut microbiota, there are relatively few deep lineages, with Firmicutes and 412 
Bacteroidetes generally dominant in most surveys (11, 29). These observations 413 
most likely reflect the influence of a variety of ecologic and evolutionary 414 
constraints on the gut microbial community (28, 29). Our results, demonstrating 415 
marked similarity between the gut microbiota from individual animals, albeit 416 
among individuals with identical genetic background maintained in a tightly 417 
controlled environment, provide strong evidence that the gut microbial community 418 
represents a stable ecosystem. This high degree of similarity also provides 419 
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evidence for the existence of community “assembly rules” that govern the 420 
establishment and stability of these microbial consortia. 421 
Perhaps the more critical assumption in experiments that involve antibiotic 422 
manipulation of the indigenous gut microbiota is that drug treatment results in 423 
reproducible alterations of the microbial community structure. The relative 424 
stability of the indigenous microbiota has been debated. From an ecological 425 
standpoint, the term stability (also commonly referred to as robustness) 426 
encompasses a number of components (2, 31). One aspect is temporal stability, 427 
which is the constancy of community structure over time. In addition, the term 428 
resistance refers to the ability of a community to maintain a given structure in the 429 
setting of a perturbation, while resilience is the ability of a community to return to 430 
its baseline structure following a perturbation in community structure. In this 431 
regard, if a community exhibits temporal stability, this implies the presence of 432 
resistance and resilience in the community structure as one assumes that most 433 
communities will experience ecologic stress at some point in time. 434 
A number of studies have indicated that an individual’s gut microbiota can 435 
have a relatively stable community composition over a period of months to years 436 
(36, 49, 58, 63). These observations have led to the conclusion that the 437 
community of microbes in the gut is relatively resistant to perturbation by various 438 
ecologic stressors. Subsequent environmental influences including diet, host 439 
genetics, medication use, and exposure to infectious agents can all have an 440 
influence on the resultant microbial community (11). It has been reported that 441 
short-term administration of antibiotics (a 7 day course of clindamycin) could 442 
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result in long-term changes in the structure of the fecal microbiota of humans (12, 443 
25, 32). In all of these human studies, there was considerable individual baseline 444 
variation in the microbiota, which made it difficult to make inter-individual 445 
comparisons in the microbiota responses.  446 
Although human studies such as these are important, one advantage of 447 
conducting murine experiments as described herein is that the ability to conduct 448 
true controlled, replicate experiments. Our replicate experiments allowed us to 449 
detect consistent shifts in the gut microbial community in the response to 450 
antibiotic administration. The reproducibility of these changes indicates that even 451 
if the influences on microbial community structure are complex and numerous, 452 
the community will exhibit stereotypic responses, if ecologic stressors are 453 
consistently applied. We observed reproducible shifts in the community structure 454 
of the gut microbiota following antibiotics including significant alterations in both 455 
the richness and distribution of 16S V6 phylotypes. The power of a deep survey 456 
of diversity allowed us to demonstrate that certain low abundance phylotypes 457 
present at baseline could become dominant in response to the shift in 458 
environmental conditions brought about by antibiotic administration. In control 459 
animals, 16S V6 tag sequences corresponding to members of the family 460 
Enterobacteriaceae comprised only a small fraction of the populations (1%). 461 
During administration of amoxicillin, metronidazole and bismuth (AMB), this 462 
group of organisms became the most dominant phylotype, indicating that this 463 
antibiotic regimen created an environment that somehow favored this taxonomic 464 
group of organisms. Simple resistance to the antibiotics cannot entirely explain 465 
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this observation as other phylotypes were unchanged in relative abundance 466 
following AMB administration, but did not undergo the remarkable relative 467 
expansion during drug treatment exhibited by the Enterobacteriaceae.  468 
In this case, the gut microbial community exhibited resilience as the 469 
community structure shifted back towards the baseline state following cessation 470 
of the AMB treatment. However, the ability of this community to recover following 471 
antibiotic disturbance was not absolute. The administration of cefoperazone also 472 
caused dramatic shifts in community structure, but in this case, diversity did not 473 
recover even six weeks after the discontinuation of the drug. Rarefaction analysis 474 
revealed a persistent, significant decrease in overall species richness in the gut 475 
community following cefoperazone administration. However, the addition of an 476 
untreated mouse to cages of cefoperazone-treated animals during the recovery 477 
phase allowed complete restoration of diversity, presumably through natural 478 
coprophagic activity. This observation indicates that cefoperazone administration 479 
did not change host physiology, as exposure to a baseline microbiota resulted in 480 
normalization of the community structure. Additionally, we infer that the baseline 481 
community structure is “preferred” since all four animals in the cage possessed a 482 
community that we not distinguish from that in untreated control animals. Since 483 
the donor animal were exposed to the altered community present in the 484 
cefoperazone-treated animals, it is possible that the resultant communities would 485 
possess the antibiotic-altered community structure or an intermediate structure. 486 
The reasons for the observed differences in community resilience are not 487 
entirely clear. The ecologic disturbance mediated by cefoperazone appears to 488 
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have overcome the community resilience, potentially due to different spectra of 489 
anti-microbial activity.  Regardless of the underlying reasons for the differences 490 
in observed community resilience, from an experimental standpoint it is important 491 
to understand that manipulation of the indigenous gut microbiota by various 492 
antibiotic regimens may result in altered community structures that persist even 493 
after the antibiotic is discontinued. Whether or not the gut community returns to 494 
the baseline state after perturbation can influence the conclusions that can be 495 
drawn from a particular experiment. 496 
The implications of long-lasting changes in community diversity following 497 
antibiotic administration are several-fold. Even though the microbial composition 498 
of the animals that recovered from cefoperazone treatment remained altered 499 
compared to baseline, overall bacterial biomass returned to the level observed in 500 
control mice. It has been postulated that functional redundancy in complex 501 
microbial communities can allow an altered community to perform equivalent 502 
ecosystem functions as the original community (2). Studies are ongoing to 503 
determine if the specific alterations in the gut microbiota result in any significant 504 
changes in gut ecosystem functioning. 505 
One function of the gut microbiota that has captured our attention is that of 506 
“colonization resistance”, the ability of the indigenous microbiota to prevent 507 
ingress of pathogens into the gut community (16, 18, 59). Antibiotic associated 508 
colitis resulting from Clostridium difficile infection may result from a loss of the 509 
intrinsic colonization resistance of the gut microbiota (4, 38). Theoretically, the 510 
administration of antibiotics could disturb the indigenous microbiota allowing C. 511 
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difficile spores encountered in the environment to germinate and successfully 512 
colonize the gut (4, 61). Although C. difficile infection responds to the 513 
administration of specific anti-microbial therapy, including metronidazole or 514 
vancomycin, recurrence following the end of C. difficile therapy has become an 515 
increasing problem (35). In a previous study, we have provided evidence that 516 
recurrent C. difficile infection is associated with a decrease in fecal microbial 517 
diversity (7). This observation is in line with the fact that the administration of 518 
stool from healthy individuals to patients with recurrent C. difficile can break the 519 
cycle of recurrence (1, 57). The data presented here indicate that antibiotic 520 
therapy of sufficient magnitude can result in an altered microbial community. It 521 
remains to be determined if this can be directly correlated with a loss of 522 
colonization resistance, but our findings provide evidence that antibiotic 523 
administration can result in long term decreases in gut microbial diversity, which 524 
in turn is associated with recurrent C. difficile disease. 525 
As we learn more about the intricate relationship between the gut 526 
microbiota and their host we may find that unintended disturbance of this 527 
microbial community will have significant deleterious health effects. A more 528 
complete understanding of the ecologic forces that determine the formation and 529 
maintenance of microbial community structures could lead to novel ways to 530 
prevent or treat diseases that result from disruptions of the gut microbiota. 531 
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Figure legends 734 
 735 
Figure 1. Schemata for antibiotic administration. A. Fifteen C57BL/6 IL-10-/- 736 
mice received the combination of amoxicillin, metronidazole and bismuth in their 737 
chow for 10 days while 10 animals remained on control chow. Mice were either 738 
euthanized immediately after antibiotic administration or after a 2-week period of 739 
recovery on non-medicated chow. Control animals remained on non-medicated 740 
chow for the entire experiment. B. Five animals remained on sterile water while 741 
15 mice were treated with 0.5 mg/ml of cefoperazone in sterile drinking water for 742 
10 days. The antibiotic-treated animals were subsequently divided into three 743 
groups. One group of 3 animals was immediately sacrificed. One group of 6 744 
animals (divided into two cages) was returned to sterile water without antibiotics 745 
for a 6-week recovery period. A final group of 6 animals (also divided into two 746 
cages) was returned to water without antibiotics, and a non-treated control 747 
mouse was added to the cage for the 6-week recovery period. The cecae of all 748 
animals were harvested for microbial community analysis. 749 
 750 
Figure 2. Comparison of the microbial community composition in the cecae 751 
of antibiotic treated mice. Over one million V6 sequence tags were retrieved 752 
and classified from cecal DNA purified from untreated mice (Control), animals 753 
that received amoxicillin, metronidazole and bismuth (AMB) in chow for 10 days 754 
(Antibiotic Treated) or AMB-treated mice that were allowed to recover on plain 755 
chow for two weeks (Recovery). The sequence tags were classified to the level 756 
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of bacterial division (phylum). The pie charts show the distribution of the pooled 757 
tags for each experimental group with the mean ± S.D. distribution of tags 758 
recovered from each individual animal is indicated. 759 
 760 
Figure 3. Genus level diversity of the gut communities in the cecae of 761 
control animals. Approximately 16,000 V6 SSU hypervariable region tags were 762 
retrieved from the cecal mucosa-associated microbiota from each of three wild-763 
type C57BL/6 mice. Pie charts show the distribution for the most prevalent 764 
taxonomically assigned tags while the percentages for the 12 most common 765 
assignments is indicated below. Bray-Curtis similarities were calculated for each 766 
pairwise comparison. The nonparametric Chao1 diversity estimator was 767 
calculated for each community based on 97% sequence similarity. 768 
 769 
Figure 4. Comparison of microbial communities in cefoperazone-treated 770 
animals. Over 300,000 V6 sequence tags were retrieved from the cecae of 771 
cefoperazone treated mice that recovered from drug treatment in the presence or 772 
absence of an untreated “donor” animal. The tags were assigned a taxonomy at 773 
the level of genus and the pair-wise Bray-Curtis distance calculated for all 774 
possible comparisons. The Bray-Curtis values are presented in a heatmap 775 
fashion as a color-coded distance matrix with the most similar (Bray-Curtis 776 
similarity of 1.0) represented by blue and the most dissimilar (Bray-Curtis 777 
similarity of 0.0) represented in red. The housing of the animals is indicated and 778 
the animals that served as “donor” in each cage are marked with a star. 779 
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 780 
Figure 5 Genus level diversity of the gut communities from cefoperazone-781 
treated animals. The taxonomic assignments of V6 tags from untreated animals 782 
(control), animals that recovered without an untreated animal (isolated recovery) 783 
and animals that recovered in the presence of an untreated animal (donor 784 
recovery) are shown. The pie charts show the most abundant genus level 785 
assigned tags for the pooled animals in each experimental group. The average (± 786 
S.D.) distribution of tags recovered from each individual animal is indicated 787 
below. ND = not detected. 788 
 789 
Figure 6 Rarefaction analysis of microbial communities from cefoperazone 790 
treated animals. The number of assigned phylotypes as a function of the 791 
number of tags retrieved. The V6 tags from untreated animals (control), animals 792 
that recovered without an untreated animal (isolated recovery) and animals that 793 
recovered in the presence of an untreated animal (donor recovery) were used to 794 
construct rarefaction curves with an OTU definition of >97% sequence similarity.  795 
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 796 
Table 1 Bray-Curtis similarities comparing communities from AMB-treated mice 797 
 798 
  
Control Recover Treated 
Control (n=9) 0.765 ± 0.014a1     
Recover (n=11) 0.756 ± 0.008a 0.749 ± 0.011a   
Treated (n=2) 0.212 ± 0.019b 0.205 ± 0.018b 0.845 ± 0.083a 
 799 
1
 average ± S.D. 800 
a,b
 values not connected by the same letter are significantly different. Groups 801 
were compared by ANOVA with significance set at p < 0.05 by Tukey Kramer.  802 
 803 
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Firmicutes NA Bryantella
Firmicutes Eubacteriaceae Anaerovorax
Firmicutes Burkholderiaceae Ralstonia
Firmicutes Clostridiaceae Clostridium
Firmicutes Erysiplotrichaceae Allobaculum
Firmicutes Clostridia NA
Bacteroidetes Lachnospiraceae NA
Genus level tag assignment Average percentage (±S.D.)
15 ± 2.3
8.9 ± 2.8
8.1 ± 0.8
7.9 ± 1.8
5.0 ± 0.3
3.5 ± .52
1.2 ± .72
0.91 ± 0.27
0.83 ± 0.045
0.54 ± 0.51
0.4 ± 0.14
0.3 ± 0.18
0.07 ± 0.02
0.53 ± 0.30
47 ± 2.4
0.1 ± .24
5.5 ± 3.1
1.4 ± 1.3
6.2 ± 5.9
4.1 ± 3.8
0 (ND)
0.5 ± 0.6
0 (ND)
0.8 ± 1.2
0 (ND)
0.23 ± 0.2
8.6 ± 5.4
0.023 ± 0.056
0 (ND)
73 ± 3.8
18 ± 4.1
6.1 ± 3.3
11 ± 2.5
4.9 ± 0.9
6.0 ± 1.0
1.2 ± 0.62
1.3 ± 0.3
0.8 ± 0.34
0.6 ± 0.17
0.39 ± 0.09
0.33 ± 0.24
0.45 ± 0.28
3.1 ± 2.0
0.35 ± 0.10
46 ± 7.8
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